Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Resveratrol prevents brain edema, blood-brain barrier permeability, and altered aquaporin profile in autism animal model
AU - Deckmann, Iohanna
AU - Santos-Terra, Júlio
AU - Fontes-Dutra, Mellanie
AU - Körbes-Rockenbach, Marília
AU - Bauer-Negrini, Guilherme
AU - Schwingel, Gustavo Brum
AU - Riesgo, Rudimar
AU - Bambini-Junior, Victorio
AU - Gottfried, Carmem
N1 - © 2021 International Society for Developmental Neuroscience.
PY - 2021/11/30
Y1 - 2021/11/30
N2 - Autism spectrum disorder can present a plethora of clinical conditions associated with the disorder, such as greater brain volume in the first years of life in a significant percentage of patients. We aimed to evaluate the brain water content, the blood-brain barrier permeability, and the expression of aquaporin 1 and 4, and GFAP in a valproic acid-animal model, assessing the effect of resveratrol. On postnatal day 30, Wistar rats of the valproic acid group showed greater permeability of the blood-brain barrier to the Evans blue dye and a higher proportion of brain water volume, prevented both by resveratrol. Prenatal exposition to valproic acid diminished aquaporin 1 in the choroid plexus, in the primary somatosensory area, in the amygdala region, and in the medial prefrontal cortex, reduced aquaporin 4 in medial prefrontal cortex and increased aquaporin 4 levels in primary somatosensory area (with resveratrol prevention). Valproic acid exposition also increased the number of astrocytes and GFAP fluorescence in both primary somatosensory area and medial prefrontal cortex. In medial prefrontal cortex, resveratrol prevented the increased fluorescence. Finally, there was an effect of resveratrol per se on the number of astrocytes and GFAP fluorescence in the amygdala region and in the hippocampus. Thus, this work demonstrates significant changes in blood-brain barrier permeability, edema formation, distribution of aquaporin 1 and 4, in addition to astrocytes profile in the animal model of autism, as well as the use of resveratrol as a tool to investigate the mechanisms involved in the pathophysiology of autism spectrum disorder.
AB - Autism spectrum disorder can present a plethora of clinical conditions associated with the disorder, such as greater brain volume in the first years of life in a significant percentage of patients. We aimed to evaluate the brain water content, the blood-brain barrier permeability, and the expression of aquaporin 1 and 4, and GFAP in a valproic acid-animal model, assessing the effect of resveratrol. On postnatal day 30, Wistar rats of the valproic acid group showed greater permeability of the blood-brain barrier to the Evans blue dye and a higher proportion of brain water volume, prevented both by resveratrol. Prenatal exposition to valproic acid diminished aquaporin 1 in the choroid plexus, in the primary somatosensory area, in the amygdala region, and in the medial prefrontal cortex, reduced aquaporin 4 in medial prefrontal cortex and increased aquaporin 4 levels in primary somatosensory area (with resveratrol prevention). Valproic acid exposition also increased the number of astrocytes and GFAP fluorescence in both primary somatosensory area and medial prefrontal cortex. In medial prefrontal cortex, resveratrol prevented the increased fluorescence. Finally, there was an effect of resveratrol per se on the number of astrocytes and GFAP fluorescence in the amygdala region and in the hippocampus. Thus, this work demonstrates significant changes in blood-brain barrier permeability, edema formation, distribution of aquaporin 1 and 4, in addition to astrocytes profile in the animal model of autism, as well as the use of resveratrol as a tool to investigate the mechanisms involved in the pathophysiology of autism spectrum disorder.
KW - Animals
KW - Antioxidants/pharmacology
KW - Aquaporin 4/metabolism
KW - Astrocytes/metabolism
KW - Autistic Disorder/metabolism
KW - Blood-Brain Barrier/drug effects
KW - Brain/drug effects
KW - Brain Edema/prevention & control
KW - Disease Models, Animal
KW - Female
KW - Male
KW - Permeability/drug effects
KW - Rats
KW - Rats, Wistar
KW - Resveratrol/pharmacology
U2 - 10.1002/jdn.10137
DO - 10.1002/jdn.10137
M3 - Journal article
C2 - 34196408
VL - 81
SP - 579
EP - 604
JO - International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
JF - International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
SN - 0736-5748
IS - 7
ER -